Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.
Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.
People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.
Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.
Editor's Picks
